Anti-KIR3DL2 / CD158k Reference Antibody (lacutamab) is a monoclonal antibody designed for research purposes, serving as a reference standard that mimics the therapeutic lacutamab. It specifically targets the KIR3DL2 receptor (also known as CD158k), which is overexpressed on malignant T-cells in hematologic malignancies such as cutaneous T-cell lymphoma (CTCL), including Sézary syndrome.

This reference antibody is used in laboratory settings to study immune-mediated mechanisms, including antibody-dependent cellular cytotoxicity (ADCC), and to evaluate potential targeted therapies. It enables researchers to investigate KIR3DL2 expression as a biomarker for disease severity and treatment response in chronic lymphoproliferative disorders. Ideal for in vitro assays, flow cytometry, and preclinical studies assessing efficacy and specificity in relapsed or refractory patient models.

Note: This is a research-grade reagent and not intended for clinical use or human administration.